Skip to content

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$11.49B+2.6%
Amgen logo
AmgenAMGN
$8.62B+5.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$17M-39.3%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$3M-60.9%
Incyte logo
IncyteINCY
$1.27B+20.9%

Other financials

Income statement

See full
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s total revenue?
IDEAYA Biosciences, Inc. (IDYA) reported total revenue of $6.56M in Q1 2026.
What is the long-term trend for IDEAYA Biosciences, Inc.'s total revenue?
Over 3 years (2021 to 2024), IDEAYA Biosciences, Inc.'s total revenue has grown at a -37.0% compound annual growth rate (CAGR), from $27.94M to $7M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.